Kutatási jelek – Signal Engine

• BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR+ NSCLC — NSCLC
• Mesothelioma malignant recurrent – Treatment – Overview of Information and Clinical Research — Malignant pleural mesothelioma
• Trials and Studies — Ewing sarcoma
• Cancer Cell Line Encyclopedia Data Suggest that Ligands for ERBB Family Receptors May Drive BRAF-WT Melanomas — Melanoma
• FDA Grants Accelerated Approval to Zongertinib (Hernexeos) for Non-Squamous NSCLC with HER2 TKD Mutations — NSCLC
• New research reveals why some esophageal cancers are so hard to treat — Head and neck squamous cell carcinoma
• The Future of Esophageal Cancer Care: Tailoring Surgery and Chemoradiation with Precision Tools — Esophageal cancer
• Targeted Therapy for Nasopharyngeal Cancer — Nasopharyngeal carcinoma
• ASCO GU 2026: Trastuzumab Deruxtecan in Pretreated Patients with HER2-Expressing Bladder Cancer: Final Results from the Bladder Cancer Cohort in Part 1 of DESTINY-PanTumor02 — Bladder cancer
• Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers — Gastric cancer
• Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer — NSCLC
• Research | Cobb Lab | UT Southwestern, Dallas, Texas — NSCLC
• UCSF Bladder Cancer Trial: Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer — Bladder cancer
• Osimertinib with or without savolitinib as first‑line treatment for MET‑aberrant, EGFR‑mutant NSCLC: randomized phase 2 trial (FLOWERS) — NSCLC
• Trial literature on neuroblastoma — Neuroblastoma
• StrateGIST 3: IDRX/Sunitinib for GIST after imatinib — Gastrointestinal stromal tumor
• Genome‑wide association study meta‑analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk — Ewing sarcoma
• Lynch Syndrome - Hereditary Nonpolyposis Colorectal Cancer (HNPCC) — Colorectal cancer
• ELCC 2026: Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study) — NSCLC
• Acute Lymphoblastic Leukemia (ALL) — Lymphoma